- GlobeNewswire•16 days ago
CAMBRIDGE, Mass., Feb. 07, 2017-- Epizyme, Inc., a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that the Company has elected industry veteran Kevin Conroy, ...
- GlobeNewswire•21 days ago
CAMBRIDGE, Mass., Feb. 02, 2017-- Epizyme, Inc., a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that the Company will present at the following investor ...
- Zacks•last month
Pluristem Therapeutics (PSTI) has completed patient enrollment in a phase II study on PLX-PAD cells for the treatment of intermittent claudication.
EPZM : Summary for Epizyme, Inc. - Yahoo Finance
Epizyme, Inc. (EPZM)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||8.15 x 100|
|Day's Range||11.95 - 12.50|
|52 Week Range||7.02 - 13.65|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-6.56|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|